Acknowledgments
We would like to acknowledge the following individuals at Thermo Fisher (Patheon) for their excellent contribution to the drug development process: Zhimin Liu, PhD, David Kuo, Nathan Bartlett, Cole Kratzer, John Burke, and Dwight Adams. We are grateful of the ICON personnel of the phase I unit in San Antonio, Texas, for their efforts, especially of Mary Mislak, Denise Haak, and Jessica Martinez. We would like to express our gratitude to Magdalena Mecking and Falko Hofmann from Lexogen GmbH for all of the RNA-sequencing-related data. This study was funded by 